March 2022 marks the official commencement of a collaboration between 3Sixty Biopharmaceuticals and Adcock lngram’s OTC division. As a result of this collaboration, Adcock Ingram OTC will take over the sales and distribution of 3Sixly Biopharmaceuticai’s products.
